A novel EGFR-targeted gene delivery system based on complexes self-assembled by EGF, DNA, and activated PAMAM dendrimers

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4625-4635

  Yin, Zhe ^a   Liu, Nan ^a   Ma, Mingshu ^a   Wang, Lan ^a   Hao, Yanli ^a   Zhang, Xiaoning ^a  

^a Tsinghua University   (China)

Author keywords

Activated dendriplexes; EGFR targeting; Self assembled EGF modification; Transfection efficiency

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DENDRIMER; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PLASMID DNA; POLYAMIDOAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; FLUORESCENCE IMAGING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROCESS DEVELOPMENT;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; DENDRIMERS; DNA; DRUG CARRIERS; DRUG STABILITY; EPIDERMAL GROWTH FACTOR; FEMALE; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; PARTICLE SIZE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPECTROSCOPY, NEAR-INFRARED; TRANSFECTION;

EID: 84870367420     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S30671     Document Type: Article

References (34)

1. Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today. 2005;10(1):35-43.
2. Sampathkumar SG, Yarema KJ. Targeting cancer cells with dendrimers. Chem Biol. 2005;12(1):5-6.
3. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136-151.
4. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63(3):131-135.
5. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615-627.
6. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev. 2005;57(15):2215-2237.
7. Lee CC, MacKay JA, Frechet JM, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol. 2005;23(12):1517-1526.
8. Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today. 2001;6(8):427-436.
9. Mamede M, Saga T, Ishimori T, etal. Hepatocyte targeting of 111 In-labeled oligo-DNA with avidin or avidin-dendrimer complex. J Control Release. 2004;95(1):133-141.
10. Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev. 2005;57(15):2106-2129.
11. Zhang Y, Sun Y, Xu X, etal. Synthesis, biodistribution, and microsingle photon emission computed tomography (SPECT) imaging study of technetium-99m labeled PEGylated dendrimer poly(amidoamine) (PAMAM)-folic acid conjugates. J Med Chem. 2010;53(8):3262-3272.
12. Pillai VC, Yesudas R, Shaik IH, etal. Delivery of NADPH-cytochrome P450 reductase antisense oligos using avidin-biotin approach. Bioconjug Chem. 2010;21(2):203-207.
13. Vlasov GP, Lesina EA, Korol'kov VI, etal. Optimization of transfection properties of DNA-lysine dendrimer complexes. Bioorg Khim. 2005;31(2):167-174.
14. Choi JS, Park JS. Supramolecular self-assembly of poly(ethylene glycol)-block-poly (L-lysine) dendrimer with plasmid DNA. Methods Mol Med. 2001;65:23-33.
15. Froehlich E, Mandeville JS, Weinert CM, Kreplak L, Tajmir-Riahi HA. Bundling and aggregation of DNA by cationic dendrimers. Biomacromolecules. 2011;12(2):511-517.
16. Froehlich E, Mandeville JS, Kreplak L, Tajmir-Riahi HA. Aggregation and particle formation of tRNA by dendrimers. Biomacromolecules. 2011;12(7):2780-2787.
17. Froehlich E, Mandeville JS, Arnold D, Kreplak L, Tajmir-Riahi HA. Effect of PEG and mPEG-anthracene on tRNA aggregation and particle formation. Biomacromolecules. 2012;13(1):282-287.
18. Navarro G, Tros de Ilarduya C. Activated and non-activated PAMAM dendrimers for gene delivery in vitro and in vivo. Nanomedicine. 2009;5(3):287-297.
19. Kuo JH, Liou MJ, Chiu HC. Evaluating the gene-expression profiles of HeLa cancer cells treated with activated and nonactivated poly(amidoamine) dendrimers, and their DNA complexes. Mol Pharm. 2010;7(3):805-814.
20. Kandala PK, Wright SE, Srivastava SK. Blocking EGFR activation suppresses ovarian tumor growth in vitro and in vivo. J Pharmacol Exp Ther. 2012;34(1):24-32.
21. Frederiksen KS, Abrahamsen N, Cristiano RJ, Damstrup L, Poulsen HS. Gene delivery by an epidermal growth factor/DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor. Cancer Gene Ther. 2000;7(2):262-268.
22. Chen J, Gamou S, Takayanagi A, Ohtake Y, Ohtsubo M, Shimizu N. Receptor-mediated gene delivery using the Fab fragments of anti-epidermal growth factor receptor antibodies: improved immunogene approach. Cancer Gene Ther. 1998;5(6):357-364.
23. Yuan Q, Lee E, Yeudall WA, Yang H. Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery. Oral Oncol. 2010;46(9):698-704.
24. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta. 2006;1766(1):120-139.
25. Thomas TP, Shukla R, Kotlyar A, etal. Dendrimer-epidermal growth factor conjugate displays superagonist activity. Biomacromolecules. 2008;9(2):603-609.
26. Zhang Q, Chen S, Zhuo RX, Zhang XZ, Cheng SX. Self-assembled terplexes for targeted gene delivery with improved transfection. Bioconjug Chem. 2010;21(11):2086-2092.
27. Kruger JS, Reddy KB. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Mol Cancer Res. 2003;1(11):801-809.
28. Shcharbin D, Pedziwiatr E, Bryszewska M. How to study dendriplexes I: Characterization. J Control Release. 2009;135(3):186-197.
29. Mounkes LC, Zhong W, Cipres-Palacin G, Heath TD, Debs RJ. Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J Bio Chem. 1998;273(40):26164-26170.
30. Mislick KA, Baldeschwieler JD. Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc Natl Acad Sci U S A. 1996;93(22):12349-12354.
31. Tang MX, Redemann CT, Szoka FC Jr. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem. 1996;7(6):703-714.
32. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer. 2001;94(6):774-782.
33. Duncan R. Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm Sci Technolo Today. 1999;2(11):441-449.
34. Zelphati O, Uyechi LS, Barron LG, Szoka FC Jr. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim Biophys Acta. 1998;1390(2):119-133.